Bayer AG Gets EU Approval for Gadovist For Children Aged 2-6 Years

Published: Jan 30, 2012

German pharmaceutical company Bayer AG (BAYN.XE) said Friday it got approval for use of Gadovist 1.0 in children aged two to six years in the Europe Union. Gadovist is a contrast medium, which is injected to make diseases visible in magnetic resonance tomography examinations, an imaging technique. It is approved for the most frequently conducted contrast enhanced magnetic resonance tomography examinations, the company said in a press release.

Back to news